



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/501,238	10/21/2004	Ana Chudzinski-Tavassi	4705-0105PUS1	5260
2292	7590	07/30/2008	EXAMINER	
BIRCH STEWART KOLASCH & BIRCH			ALLEN, MARIANNE P	
PO BOX 747			ART UNIT	PAPER NUMBER
FALLS CHURCH, VA 22040-0747			1647	
NOTIFICATION DATE		DELIVERY MODE		
07/30/2008		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com



## UNITED STATES DEPARTMENT OF COMMERCE

## U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10501238	10/21/2004	CHUDZINSKI-TAVASSI ET AL.	4705-0105PUS1

## EXAMINER

Marianne P.. Allen

ART UNIT	PAPER
1647	20080507

## DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

## Commissioner for Patents

The amendment filed on 2/28/08 canceling all claims drawn to the elected invention and presenting only claims drawn to a non-elected invention is non-responsive (MPEP § 821.03). The remaining claims are not readable on the elected invention because they are directed to a different method of treatment. New claim 20 is directed to a method of preventing severe vascular thrombosis in a patient comprising administering to said patient a protein comprising the amino acid sequences set forth in SEQ ID NOS: 1, 2, 3, 4, and 5.

Elected claim 14 was cancelled and replaced by claim 17 for examination. Claim 14 was directed to the utilization of the prothrombin activator of claim 13, characterized by enabling to be using prothrombin activator as a dysfibrinogenizing agent in prothrombotic state patients. Claim 17 was directed to a method for treating prothrombotic disorders in an individual in need thereof comprising administering to said individual an effective dose of a prothrombin activator protease comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 2, 3, 4 and 5, wherein said effective dose prevents blood clot formation.

The method of claim 20 differs significantly from claims 14 and 17 in the method steps performed and the intended result.

Furthermore, there is no basis in original claim 14; page 16, lines 18-28; and/or pages 24-38 for the method and limitations set forth in new claims 20-23.

Since the above-mentioned amendment appears to be a *bona fide* attempt to reply, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, whichever is longer, from the mailing date of this notice within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD UNDER 37 CFR 1.136(a) ARE AVAILABLE.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marianne P. Allen whose telephone number is 571-272-0712. The examiner can normally be reached on Monday-Friday, 5:30 am - 2:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao, can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

*/Marianne P. Allen/  
Primary Examiner, Art Unit 1647*